Reata Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for cancer, inflammation, and neurodegenerative diseases. It offers antioxidant inflammation modulating drugs, as well as drugs that correct protein misfolding. The company also develops drugs for the treatment of renal/cardiovascular and autoimmune diseases. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is based in Irving, Texas.

from http://reatapharma.com/about-us/our-story/

Research Grants 1 show all


$100K
2005

Patents 502show all

  • 108
    C07D - Heterocyclic compounds
  • 99
    C07C - Acyclic or carbocyclic compounds
  • 79
    C07J - Steroids
  • 50
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 22
    A61K - Preparations for medical, dental, or toilet purposes
  • 9
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 3
    C07B - General methods of organic chemistry
  • 3
    C07H - Sugars

Clinical Trials 86show all

28Phase 322Phase 120Phase 28N/A7Other

SEC Filings show all


46
8-K

12
10-Q

6
D

4
10-K

1
S-1

Contact Information

2801 Gateway Drive Suite 150
Irving, TX 75063
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$1,323,949,84051-1002020-06-11Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2020-06-11$350,000,000Post Ipo EquityBlackstone Life Sciences
2019-11-18$505,000,000Post Ipo Equity
2009-09-25$16,977,840Series Unknown
2010-02-26$1,972,000Series Unknown
2004-11-12$12,000,000Series CThe University of Texas at Austin, Ojai Goliad, Startech Early Ventures, Cardinal Investment Co.
2007-07-08$25,000,000Series ENovo Holdings, CPMG
2017-04-03$35,000,000Post Ipo DebtSilicon Valley Bank, Oxford Finance LLC
2011-07-13$300,000,000Series Unknown
2010-07-12$78,000,000Private EquityNovo Holdings, CPMG

SEC Form D Funding Events

DateOfferedSoldType
2011-07-13$300,000,000$300,000,000Equity
2010-10-05$79,333,335$16,977,840Equity, Option to Acquire, Security to be Acquired
2010-02-26$1,972,000$1,972,000Equity
2009-09-28$79,333,335$16,977,840Equity, Option to Acquire, Security to be Acquired
2008-12-10Unknown Unknown Other (Paper Filing)

Key Executives

  • J. Warren Huff
    Executive Officer, Director
  • Jack B. Nielsen
    Director
  • Dennis Stone
    Director
  • James Bass
    Director
  • Jason D. Wilson
    Executive Officer
  • William Christian Wigley
    Executive Officer
  • Eric Grossman
    Executive Officer
  • Kent McGaughy
    Director
  • Edward W. Rose
    Director
  • Charles A. Sanders
    Director
  • Colin Meyer
    Executive Officer
  • Melissa Krauth
    Executive Officer
  • Robert M. Kral, Jr.
    Executive Officer
  • John Walling
    Executive Officer
  • Melean Visnick
    Executive Officer
  • Paul Audhya
    Executive Officer
  • Catherine Fanning
    Executive Officer
  • Casi DeYoung
    Executive Officer
  • Nancy Wysenski
    Director